Expert Interviews: Leading ME/CFS Researchers and Clinicians Share Insights
The ME/CFS field features dedicated researchers and clinicians whose work has transformed understanding of the disease. This collection of synthesized insights from leading experts provides patients and healthcare providers with authoritative perspectives on diagnosis, treatment, and the future of ME/CFS research.
These insights are compiled from published interviews, conference presentations, and public educational materials from recognized experts in the field.
Dr. David Systrom — Exercise Physiology and Hemodynamics
Dr. David Systrom, a pulmonary and critical care physician at Brigham and Women’s Hospital, has conducted groundbreaking research on exercise intolerance in ME/CFS through invasive cardiopulmonary exercise testing (iCPET).
Key insight on PEM: “What we’ve discovered through iCPET is that ME/CFS patients have a fundamental problem with oxygen delivery and extraction at the cellular level. The blood vessels don’t dilate properly during exercise, and the muscles can’t extract oxygen efficiently. This explains why even mild activity can trigger PEM — it’s not deconditioning, it’s a physiological impairment.”
Diagnostic implications: Dr. Systrom’s research demonstrates that standard exercise testing often misses the physiological abnormalities in ME/CFS because the tests aren’t sensitive enough. iCPET reveals abnormalities that conventional testing misses, providing objective evidence of the disease.
Treatment approach: “We’re learning that treating the autonomic dysfunction — supporting blood volume, improving vascular tone — can improve exercise capacity in some patients. It’s not a cure, but it can expand the energy envelope enough to improve quality of life.”
Dr. Nancy Klimas — Immunology and Systems Biology
Dr. Nancy Klimas, director of the Institute for Neuro-Immune Medicine at Nova Southeastern University, has spent decades studying immune dysfunction in ME/CFS.
Key insight on immune dysfunction: “ME/CFS patients have a distinctive immune signature — reduced NK cell function, elevated cytokines, and evidence of immune activation. This isn’t depression or deconditioning. We can measure these abnormalities, and they point to a disease process that requires targeted treatment.”
Systems biology approach: “ME/CFS isn’t a single-organ disease. It involves the immune system, nervous system, endocrine system, and energy metabolism all interacting. Our computational models help us understand these interactions and identify the most promising intervention points.”
On research methodology: “The biggest challenge in ME/CFS research has been methodology. Many early studies had fundamental design flaws — measuring patients during remission rather than during flares, not accounting for PEM, or using inadequate controls. Rigorous methodology is essential for meaningful results.”
Dr. Lucinda Bateman — Clinical Care and Patient Advocacy
Dr. Lucinda Bateman, founder of the Bateman Horne Center, is one of the most experienced ME/CFS clinicians and a tireless advocate for patient-centered care.
Key insight on clinical practice: “The most important thing for physicians to understand is that ME/CFS patients know their bodies. They can tell you exactly what their limits are, what triggers their symptoms, and what helps. Our job is to listen, validate, and help them manage their condition effectively.”
On pacing: “Energy management is the cornerstone of ME/CFS care. It’s not about doing less — it’s about doing the right things at the right intensity at the right time. Patients who master pacing stabilize their condition and often improve. Those who push through crashes continue declining.”
Advice for patients: “Find a physician who believes you and is willing to learn. You don’t need a specialist for basic management — you need a partner who will work with you. Bring educational materials to your appointments. Advocate for yourself, but also take care of yourself.”
Dr. Ian Lipkin — Viral Triggers and the Microbiome
Dr. Ian Lipkin, a renowned infectious disease researcher at Columbia University, has studied viral triggers and microbiome changes in ME/CFS.
Key insight on viral triggers: “Our research has identified evidence of viral reactivation in ME/CFS patients — particularly herpesviruses. This doesn’t mean viruses cause all ME/CFS, but for a significant subgroup, antiviral strategies may be worth investigating.”
Microbiome findings: “We’ve found consistent differences in the gut microbiome of ME/CFS patients compared to healthy controls. The gut-immune axis is clearly involved in the disease process. Modifying the microbiome is a promising therapeutic avenue, though we’re still in early stages.”
On the long COVID connection: “The overlap between long COVID and ME/CFS is striking — probably 50% or more of long COVID patients meet ME/CFS diagnostic criteria. This convergence is accelerating research into post-viral chronic illness and may finally provide the breakthroughs ME/CFS patients have waited decades for.”
Dr. Peter Rowe — Pediatric ME/CFS and Treatment Innovation
Dr. Peter Rowe, a professor of medicine at Johns Hopkins, has specialized in pediatric ME/CFS and innovative treatment approaches.
Key insight on children and adolescents: “ME/CFS in children and adolescents is underdiagnosed and often dismissed as ‘growing pains’ or school avoidance. Early diagnosis and appropriate management can prevent the severe functional decline that occurs when the condition is ignored or inappropriately treated.”
Fludrocortisone research: “Our research on fludrocortisone — a medication that expands blood volume — showed significant improvement in symptoms for many ME/CFS patients. This addresses one of the core physiological problems: inadequate blood volume and perfusion.”
On graded exercise therapy: “The evidence is clear that graded exercise therapy is harmful for ME/CFS patients. The 2021 NICE guideline reversal was a watershed moment. Physicians who continue to prescribe GET are not following the evidence and are potentially causing harm.”
Dr. Jose Montoya — Inflammation and Immunomodulation
Dr. Jose Montoya, a professor of medicine at Stanford University, has researched inflammatory markers and immunomodulatory treatments in ME/CFS.
Key insight on inflammation: “ME/CFS patients have elevated inflammatory markers — particularly cytokines — that distinguish them from healthy controls and from patients with depression. This inflammatory signature provides objective evidence of disease and points toward immunomodulatory treatment.”
Rituximab trial: “Our RituxME trial was negative overall, but subgroup analysis suggested benefit in some patients. This highlights the heterogeneity of ME/CFS — it’s likely multiple diseases under one umbrella, and personalized treatment approaches are needed.”
On biomarkers: “We’re getting closer to diagnostic biomarkers for ME/CFS. Metabolomics, cytokine profiling, and immune phenotyping are all showing promise. Within the next decade, I believe we’ll have clinically useful tests that can diagnose ME/CFS objectively.”
Dr. Chris Snell — Activity Intolerance Research
Dr. Chris Snell, a professor emeritus at the University of the Pacific, pioneered the two-day cardiopulmonary exercise testing protocol that objectively demonstrates PEM.
Key insight on exercise testing: “The two-day CPET protocol revealed something crucial: ME/CFS patients show measurable physiological deterioration on the second day of testing. This is objective proof that exercise makes them worse — it’s not perception, it’s physiology.”
Energy envelope theory: “My research on the energy envelope showed that patients who stay within their energy limits stabilize or improve, while those who consistently exceed their limits decline. This is the scientific foundation for pacing as a treatment strategy.”
On exercise recommendations: “The idea that deconditioning causes ME/CFS has been thoroughly debunked. Our data shows that exercise doesn’t improve ME/CFS — it worsens it in most patients. The solution is not more exercise; it’s better energy management.”
Dr. Susan Levine — Clinical Management and Specialist Care
Dr. Susan Levine, an infectious disease specialist in New York, has treated ME/CFS patients for over 30 years.
Key insight on clinical management: “Every ME/CFS patient is different. The symptom profile, severity, triggers, and treatment response vary enormously. Effective management requires individualized treatment plans based on each patient’s specific presentation.”
On antiviral therapy: “I’ve seen meaningful improvement in patients with evidence of viral reactivation when treated with antiviral medications. This isn’t a universal solution, but for appropriate patients, it can be life-changing.”
Advice for physicians: “You don’t need to be an expert to help ME/CFS patients. Start by believing them, conducting thorough evaluations to exclude other conditions, and supporting energy management. Refer to specialists when needed, but don’t abandon patients just because you don’t have all the answers.”
Frequently Asked Questions
How can I access these experts for my own care? Dr. Bateman’s Bateman Horne Center offers clinical consultations (including telehealth). Dr. Klimas sees patients at Nova Southeastern University. Dr. Levine accepts new patients. The Solve ME/CFS Initiative physician directory lists additional ME/CFS-experienced clinicians. Telemedicine has expanded access significantly.
Are these experts’ recommendations evidence-based? The experts cited here base their clinical and research work on published, peer-reviewed evidence. However, ME/CFS research is evolving, and some recommendations reflect clinical experience that precedes formal trial validation. Always discuss treatment options with your own healthcare provider.
What is the most important takeaway from these experts? Several themes emerge consistently: ME/CFS is a real, physiological disease (not psychological); pacing is the cornerstone of management; graded exercise therapy is harmful; patients know their bodies and should be partners in care; and research is finally progressing toward effective treatments.
How can patients contribute to the research these experts are conducting? Participate in clinical trials listed on ClinicalTrials.gov, contribute to research registries like the Solve ME/CFS Initiative registry, donate to research organizations like the Open Medicine Foundation, and share your data and experience through patient surveys and interviews.
Summary
Leading ME/CFS researchers and clinicians consistently emphasize that ME/CFS is a serious physiological disease requiring evidence-based management. Key themes across expert perspectives include the importance of pacing over exercise, the reality of immune and autonomic dysfunction, the promise of emerging biomarkers, and the transformative impact of long COVID research on ME/CFS understanding. Patients benefit from partnering with knowledgeable healthcare providers who believe them, listen to their experience, and work collaboratively on individualized management strategies.
See our future outlook article for predictions about where ME/CFS research and treatment are heading, and our learning pathways guide for structured educational resources.